Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Age-Related Macular Degeneration
In brief
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD). Participants will receive 4 capsules of krill oil or placebo daily for a period of 3 months. Outcomes will be evaluated after 3-month treatment to assess differences between the two study groups.
Key facts
- Study ID
- NCT05465252
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- People needed
- 24
- Starts
- 2025-10-17
- Expected to finish
- 2026-05-01
- Last updated by the study team
- 2026-01-02
Who can join
Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (>63 μm and ≤125 μm) without AMD-related pigmentary abnormalities; (2) Intermediate AMD: large drusen (>125 μm), with or without AMD-related pigmentary abnormalities.
- Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin.
- Willing to sign the informed consent, and willing to attend follow-up visits for at least 3 months.
You may not qualify if…
- Any eye with disease that would interfere with the fundus examinations.
- Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia.
- Surgeries that may interfere with AMD evaluation.
- Long-term use of any medications that are associated with retinal or neural toxicities.
- History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a wash-out period of at least 8 weeks is completed prior to enrollment.
- Intraocular pressure more than 26 mmHg.
- Received cataract surgery in 3 months.
- Other conditions: subjects with severe systemic diseases; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer.
- Other conditions not suitable for the current study.
Where it is running
- Shanghai General Hospital, Shanghai Jiao Tong University — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.